REFERENCES
  1. Dhillon S. Carotegrast Methyl: First Approval. Drugs . 2022;82(9):1011-6. doi: 10.1007/s40265-022-01732-0.
  2. Sugiura T, Kageyama S, Andou A, et al. Oral treatment with a novel small molecule alpha 4 integrin antagonist, AJM300, prevents the development of experimental colitis in mice. J Crohns Colitis . 2013;7(11):e533-42. doi: 10.1016/j.crohns.2013.03.014.
  3. Yoshimura N, Watanabe M, Motoya S, et al. Safety and efficacy of AJM300, an oral antagonist of α4 integrin, in induction therapy for patients with active ulcerative colitis. Gastroenterology . 2015;149(7):1775-83.e2. doi: 10.1053/j.gastro.2015.08.044.
  4. Matsuoka K, Watanabe M, Ohmori T, et al. AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Gastroenterol Hepatol . 2022;7(7):648-57. doi: 10.1016/S2468-1253(22)00022-X.
  5. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.N Engl J Med . 2012;366(20):1870-80. doi: 10.1056/NEJMoa1107829.
  6. McGuigan C, Craner M, Guadagno J, et al. Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. J Neurol Neurosurg Psychiatry . 2016;87(2):117-25. doi: 10.1136/jnnp-2015-311100.
  7. Williamson EML, Berger JR. Diagnosis and Treatment of Progressive Multifocal Leukoencephalopathy Associated with Multiple Sclerosis Therapies. Neurotherapeutics . 2017;14(4):961-73. doi: 10.1007/s13311-017-0570-7.
  8. Fukase H, Kajioka T, Oikawa I, Ikeda N, Furuie H. Food effect on a single high dose of carotegrast methyl, an oral antagonist of α4-integrin, in healthy male subjects: a randomised, placebo-controlled, double-blind study. Clin Drug Investig . 2020;40(3):237-47. doi: 10.1007/s40261-019-00879-1.
  9. Fukase H, Kajioka T, Oikawa I, Ikeda N, Furuie H. AJM300, a novel oral antagonist of α4-integrin, sustains an increase in circulating lymphocytes: A randomised controlled trial in healthy male subjects.Br J Clin Pharmacol . 2020;86(3):591-600. doi: 10.1111/bcp.14151.
  10. Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet . 2012;380(9853):1606-19. doi: 10.1016/S0140-6736(12)60150-0.
  11. Feuerstein JD, Cheifetz AS. Ulcerative colitis: epidemiology, diagnosis, and management. Mayo Clin Proc . 2014;89(11):1553-63. doi: 10.1016/j.mayocp.2014.07.002.
  12. Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet . 2017;389(10080):1756-70. doi: 10.1016/S0140-6736(16)32126-2.
  13. Ministry of Health, Labour and Welfare, Guideline on drug interaction for drug development and appropriate provision of information. https://www.pmda.go.jp/files/000228122.pdf. Accessed April 8, 2023.
  14. Foti RS, Rock DA, Wienkers LC, Wahlstrom JL. Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation. Drug Metab Dispos . 2010;38(6):981-7. doi: 10.1124/dmd.110.032094.
  15. Denisov IG, Grinkova YV, Camp T, McLean MA, Sligar SG. Midazolam as a Probe for Drug-Drug Interactions Mediated by CYP3A4: Homotropic Allosteric Mechanism of Site-Specific Hydroxylation.Biochemistry . 2021;60(21):1670-81. doi: 10.1021/acs.biochem.1c00161.
  16. Denisov IG, Grinkova YV, McLean MA, Camp T, Sligar SG. Midazolam as a Probe for Heterotropic Drug-Drug Interactions Mediated by CYP3A4.Biomolecules . 2022;12(6):853. doi: 10.3390/biom12060853.
  17. Thummel KE, O’Shea D, Paine MF, et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther . 1996;59(5):491-502. doi: 10.1016/S0009-9236(96)90177-0.
  18. Steenholdt C, Jensen JT, Brynskov J, et al. Patient satisfaction of propofol versus midazolam and fentanyl sedation during colonoscopy in inflammatory bowel disease. Clin Gastroenterol Hepatol . 2022;20(3):559-68.e5. doi: 10.1016/j.cgh.2020.10.037.
  19. Nakase H, Uchino M, Shinzaki S, et al. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol . 2021;56(6):489-526. doi: 10.1007/s00535-021-01784-1.
  20. Varis T, Kivistö KT, Neuvonen PJ. The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone. Eur J Clin Pharmacol . 2000;56(1):57-60. doi: 10.1007/s002280050720.
  21. Lebrun-Vignes B, Archer VC, Diquet B, et al. Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. Br J Clin Pharmacol . 2001;51(5):443-50. doi: 10.1046/j.1365-2125.2001.01372.x.
  22. Skauby RH, Bergan S, Andersen AM, Vethe NT, Christensen H. In vitro assessments predict that CYP3A4 contributes to a greater extent than CYP3A5 to prednisolone clearance. Basic Clin Pharmacol Toxicol . 2021;129(6):427-36. doi: 10.1111/bcpt.13645.
  23. Lennernäs H. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet . 2003;42(13):1141-60. doi: 10.2165/00003088-200342130-00005.
  24. Molden E, Skovlund E, Braathen P. Risk management of simvastatin or atorvastatin interactions with CYP3A4 inhibitors. Drug Saf . 2008;31(7):587-96. doi: 10.2165/00002018-200831070-00004.
  25. Hirota T, Fujita Y, Ieiri I. An updated review of pharmacokinetic drug interactions and pharmacogenetics of statins. Expert Opin Drug Metab Toxicol . 2020;16(9):809-22. doi: 10.1080/17425255.2020.1801634.
  26. Ohno Y, Hisaka A, Suzuki H. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs. Clin Pharmacokinet . 2007;46(8):681-96. doi: 10.2165/00003088-200746080-00005.
  27. Ohno Y, Hisaka A, eds. Pharmacokinetic Drug Interaction Management: Basics and Practice of PISCS, 2nd Edit. Tokyo, Japan: Jiho, Inc.; 2021. Japanese.
  28. Imai H, Kotegawa T, Tsutsumi K, et al. The recovery time-course of CYP3A after induction by St John’s wort administration. Br J Clin Pharmacol . 2008;65(5):701-7. doi: 10.1111/j.1365-2125.2008.03120.x.
  29. Interview form of Lipitor ® Tablets 5mg/10mg issued on April 2014. https://www.info.pmda.go.jp/go/interview/2/671450_2189015F1023_2_1F.pdf. Japanese. Accessed April 9, 2023.
  30. Cannady EA, Suico JG, Wang MD, et al. CYP-mediated drug-drug interactions with evacetrapib, an investigational CETP inhibitor: in vitro prediction and clinical outcome. Br J Clin Pharmacol . 2015;80(6):1388-98. doi: 10.1111/bcp.12730.
  31. Skauby RH, Bergan S, Andersen AM, Vethe NT, Christensen H. In vitro assessments predict that CYP3A4 contributes to a greater extent than CYP3A5 to prednisolone clearance. Basic Clin Pharmacol Toxicol . 2021;129(6):427-36. doi: 10.1111/bcpt.13645.
  32. Kantola T, Kivistö KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther . 1998;64(1):58-65. doi: 10.1016/S0009-9236(98)90023-6.